title: Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.
abstract: OBJECTIVE
  To assess long-term golimumab efficacy/safety in patients with active psoriatic arthritis (PsA).
  
  
  METHODS
  Adult PsA patients (≥3 swollen, ≥3 tender joints, active psoriasis) were randomly assigned to subcutaneous injections of placebo, golimumab 50 mg or 100 mg every 4 weeks (q4wks) through week 20. All patients received golimumab 50 or 100 mg beginning week 24. Findings through 2 years are reported. Efficacy evaluations included ≥20% improvement in American College of Rheumatology (ACR20) response, good/moderate response in Disease Activity Scores incorporating 28 joints and C-reactive protein (DAS28-CRP), ≥75% improvement in Psoriasis Area and Severity Index (PASI75) and changes in PsA-modified Sharp/van der Heijde scores (SHS).
  
  
  RESULTS
  Golimumab treatment through 2 years was effective in maintaining clinical response (response rates: ACR20 63%-70%, DAS28-CRP 77%-86%, PASI75 56%-72%) and inhibiting radiographic progression (mean change in PsA-modified SHS in golimumab-treated patients: -0.36), with no clear difference between doses. No new safety signals were identified through 2 years. With the study's tuberculosis screening and prophylactic measures, no patient developed active tuberculosis through 2 years.
  
  
  CONCLUSIONS
  Golimumab 50 and 100 mg for up to 2 years yielded sustained clinical and radiographic efficacy when administered to patients with active PsA. Increasing the golimumab dose from 50 to 100 mg q4wks added limited benefit. Golimumab safety through up to 2 years was consistent with other antitumour necrosis factor α agents used to treat PsA. Treatment of patients with latent tuberculosis identified at baseline appeared to be effective in inhibiting the development of active tuberculosis.
authors.affiliation: Division of Rheumatology, Allergy, Immunology, University of California, , San Diego, La Jolla, California, USA.
authors.forename: Arthur
authors.initials: A
authors.lastname: Kavanaugh
authors.forename: Iain B
authors.initials: IB
authors.lastname: McInnes
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Mease
authors.forename: Gerald G
authors.initials: GG
authors.lastname: Krueger
authors.forename: Dafna D
authors.initials: DD
authors.lastname: Gladman
authors.forename: Désirée
authors.initials: D
authors.lastname: van der Heijde
authors.forename: Surekha
authors.initials: S
authors.lastname: Mudivarthy
authors.forename: Weichun
authors.initials: W
authors.lastname: Xu
authors.forename: Michael
authors.initials: M
authors.lastname: Mack
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Xu
authors.forename: Anna
authors.initials: A
authors.lastname: Beutler
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology; D002097:C-Reactive Protein / Q000276:immunology; D018572:Disease-Free Survival; D004311:Double-Blind Method; D005260:Female; D033023:Foot Joints / Q000000981:diagnostic imaging; D050823:Hand Joints / Q000000981:diagnostic imaging; D006801:Humans; D055985:Latent Tuberculosis / Q000188:drug therapy; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011859:Radiography; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D002097:C-Reactive Protein; C529000:golimumab